<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-108475</identifier>
<setSpec>0001-7310</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Deep Vein Thrombosis in a Patient With Lepromatous Leprosy Receiving Thalidomide to Treat Leprosy Reaction</dc:title>
<dc:description xml:lang="en">Thalidomide is the treatment of choice for severe or recurrent erythema nodosum leprosum. Its use has been associated with deep vein thrombosis in patients with blood disorders, however, particularly when used in combination with corticosteroids or chemotherapy. We describe a case of deep vein thrombosis in a 43-year-old man with lepromatous leprosy who was being treated with thalidomide and prednisone for a type 2 leprosy reaction (erythema nodosum leprosum); the patient also had transiently positive antiphospholipid antibody results. We stress the importance of considering deep vein thrombosis, a potentially fatal complication, in dermatology patients treated with thalidomide (AU)</dc:description>
<dc:creator>Vanaclocha, F</dc:creator>
<dc:creator>Burgués-Calderón, M</dc:creator>
<dc:creator>Hera, I. de la</dc:creator>
<dc:creator>Rivera-Díaz, R</dc:creator>
<dc:creator>Villar-Buill, M</dc:creator>
<dc:creator>Fuertes, L</dc:creator>
<dc:creator>Hebe Petiti-Martin, G</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">La talidomida es el fármaco de elección en el tratamiento del eritema nodoso leproso severo/recurrente. Su uso ha sido relacionado con trombosis venosas profundas (TVP) en pacientes con enfermedades hematológicas (especialmente cuando se le asocia con corticoides y quimioterapia). Presentamos un caso de TVP en un hombre de 43 años, con lepra lepromatosa en tratamiento con talidomida y prednisona por una leprorreación tipo 2 (eritema nodoso leproso), con anticuerpos antifosfolípidos positivos transitorios. Resaltamos la importancia de tener en cuenta esta posible complicación, potencialmente fatal, en pacientes tratados con talidomida por enfermedades dermatológicas (AU)</dc:description>
<dc:source>Actas Dermosifiliogr;104(1): 67-70, ene. 2013. ilus</dc:source>
<dc:identifier>ibc-108475</dc:identifier>
<dc:title xml:lang="es">Trombosis venosa profunda en paciente con lepra lepromatosa tratado con talidomida por leprorreacción</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d33768^s22036</dc:subject>
<dc:subject>^d23708^s22057</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d23708^s22012</dc:subject>
<dc:subject>^d14171^s22020</dc:subject>
<dc:subject>^d14171^s22073</dc:subject>
<dc:subject>^d4409</dc:subject>
<dc:type>article</dc:type>
<dc:date>201301</dc:date>
</metadata>
</record>
</ibecs-document>
